TC BioPharm (Holdings) plc American Depositary Receipt

TC BioPharm (Holdings) plc is a clinical-stage biopharmaceutical company specializing in the development of innovative immunotherapy products derived from its proprietary allogeneic gamma delta T cell platform. Founded in 2013 and headquartered in Motherwell, United Kingdom, the company focuses on advancing cell-based therapies for serious medical conditions. Its product pipeline includes OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy currently in phase 2/3 clinical trials targeting acute myeloid leukemia, and ImmuniStim, an unmodified cell therapy designed to treat viral infections and various cancers. TC BioPharm emphasizes the development of safer, cost-effective CAR-T cell therapies with the potential to address multiple cancer types and improve patient health outcomes. Operating within the biotechnology sector, TC BioPharm leverages its integrated preclinical to clinical development model to innovate in cancer and infectious disease treatment, contributing to advancements in cell therapy and immunotherapy research.